Quast et al.’s [8] trial revealed that lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, effectively delays gastric emptying, potentially improving GERD management in diabetic patients. Here, GLP1R is linked to gastroesophageal reflux disease.